<u>REMARKS</u>

Claims 1-7 are pending in the instant applications. Claim 1-4, 6 and 7 have been rejected. Claim 5 has been allowed. Claims 1-3 have been cancelled. Claim 4 has been amended to place it in order for allowance or appeal. Claim 6 has been amended to alter its dependency. After entry of these amendments, Claims 4-7 will be pending.

Rejection of Claims 1-4, 6 and 7 under 35 USC §112, first paragraph

The Examiner has maintained the rejection of Claims 1-4, 6 and 7 under 35 U.S.C. §112, first paragraph for allegedly failing to provide an adequate written description. Applicants respectfully traverse this rejection. However, without conceding the correctness of the Examiner's rejection, but to advance the prosecution of the instant application, Applicants have cancelled Claims 1-3, and amended Claim 4 in accordance with the Examiner's suggestion. In addition to the Examiner's suggested scope for R¹, R³, R⁴, R⁸, R¹⁰, R¹², R¹³ and R^c/R^{c'}, Applicants have included "heterocyclyl" within the definition of R^c and R^{c'} to cover compounds such as 8-4 on page 87 of the specification (which has a tetrahydrofuran moiety in the R^c/R^{c'} position).

In light of these amendments and cancellations, Applicants respectfully request the rejection of Claims 1-4, 6 and 7 under 35 U.S.C. §112, first paragraph, be withdrawn.

If a telephonic communication with the Applicants' representative will advance the prosecution of the instant application, please telephone the representative indicated below. Applicants believe no additional fees are due but the Commissioner is authorized to charge any fees required in connection with this response to Merck Deposit Account No. 13-2755.

Respectfully submitted,

Nicole M. Beeler

Reg. No. 45,194

Attorney for Applicants

MERCK & CO., INC.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-1077

Date: September 13, 2007